BioNTech (NASDAQ:BNTX) Trading Up 1.3% – Here’s What Happened

Shares of BioNTech SE (NASDAQ:BNTX) were up 1.3% during mid-day trading on Thursday . The company traded as high as $103.98 and last traded at $103.46. Approximately 167,580 shares were traded during mid-day trading, a decline of 79% from the average daily volume of 807,735 shares. The stock had previously closed at $102.14.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on BNTX shares. Jefferies Financial Group raised BioNTech from a “hold” rating to a “buy” rating and increased their price objective for the stock from $96.00 to $150.00 in a report on Tuesday, September 17th. JPMorgan Chase & Co. decreased their price objective on BioNTech from $125.00 to $124.00 and set a “neutral” rating for the company in a report on Monday, November 4th. UBS Group increased their price objective on BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a report on Wednesday, September 18th. Evercore ISI raised BioNTech from an “in-line” rating to an “outperform” rating and increased their price objective for the stock from $110.00 to $125.00 in a report on Tuesday. Finally, Hsbc Global Res raised BioNTech from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 2nd. Four equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $138.79.

BioNTech Trading Up 4.4 %

The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The company has a 50-day moving average price of $113.74 and a 200-day moving average price of $97.49. The company has a market capitalization of $25.56 billion, a price-to-earnings ratio of -49.27 and a beta of 0.26.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, beating the consensus estimate of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $514.08 million. During the same period in the prior year, the company earned $0.73 EPS. The business’s quarterly revenue was up 38.9% compared to the same quarter last year. Research analysts predict that BioNTech SE will post -3.68 EPS for the current fiscal year.

Institutional Investors Weigh In On BioNTech

A number of institutional investors have recently added to or reduced their stakes in the stock. Vestcor Inc acquired a new position in shares of BioNTech in the 3rd quarter worth approximately $784,000. Y Intercept Hong Kong Ltd acquired a new position in shares of BioNTech in the 3rd quarter worth approximately $718,000. XTX Topco Ltd acquired a new position in shares of BioNTech in the 3rd quarter worth approximately $459,000. State Street Corp boosted its holdings in shares of BioNTech by 2.0% in the 3rd quarter. State Street Corp now owns 155,867 shares of the company’s stock worth $18,512,000 after acquiring an additional 3,014 shares in the last quarter. Finally, Redmile Group LLC acquired a new position in shares of BioNTech in the 3rd quarter worth approximately $18,345,000. 15.52% of the stock is owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.